Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 5/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636808 | 0.88 | SCD (0.57) | SCDRBP4EPHX2KDM4EPOLB | |
| SCHEMBL2637654 | 0.84 | RBP4 (0.45) | SCDRBP4KDM4ETDP1NSD2 | |
| SCHEMBL2637754 | 0.83 | SCD (0.43) | SCDRBP4KDM4ETDP1NSD2 | |
| SCHEMBL2637789 | 0.83 | EPHX2 (0.57) | CCR8EPHX2TDP1KMT2ASIGMAR1 | |
| SCHEMBL2636571 | 0.81 | LMNA (0.45) | CCR8EPHX2POLBKMT2ASIGMAR1 | |
| SCHEMBL72136 | 0.81 | KMT2A (0.59) | CCR8EPHX2KMT2ASIGMAR1 | |
| SCHEMBL70179 | 0.80 | ALDH1A1 (0.58) | CCR8KDM4E | |
| Hydrochloric Acid SCHEMBL69896 | 0.80 | KMT2A (0.58) | SCDCCR8EPHX2KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL70782 | 0.80 | KMT2A (0.58) | SCDCCR8EPHX2KMT2ASIGMAR1 | |
| SCHEMBL70952 | 0.79 | RBP4 (0.44) | SCDRBP4EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885RBP4 1599/4885CCR8 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.